Issue link: https://htpgraphics.uberflip.com/i/538681
NORTH CAMPUS INCUBATOR (NCI) NCI has seen great growth across many of its tenants which has resulted in some office expansions - Frontier PR and Siyemi have now moved into Arch 29. UMIC was delighted to attend an "Office Warming" at NCI in recent weeks. UMIC ® UMIP ® UMI 3 INNOVATION CENTRE We have seen another successful year with tenant occupancy at around 97% UMIC continue to invest in energy reduction measures with an increase in metering across both buildings and tenants in the Incubator will soon have access to Raspberry's in each laboratory to check electricity usage on a daily basis. Recruitment is currently taking place for an Operations Manager and we hope to have a new member join the team in August. Frontier PR's 2015 has taken another exciting turn with a move into new office space and the recruitment of new staff. David Innes-Edwards, Managing Director of Frontier PR, gave us this brief overview of his company's recent success. Although the agency remains within UMIC's facility in Central Manchester, Frontier PR has doubled its office space, reflecting the company's rise over the last two years. The agency is now eight strong, following the recent recruitment of senior account manager Matt Ball and junior account executive Nick Seddon. David commented: "The opportunity to take new space within UMIC's facility represents a great move for Frontier PR. "Our new home provides the right space to satisfy Frontier PR's ambitious growth plans – whilst ensuring minimum disruption to staff or clients. "UMIC has been a tremendous support to Frontier PR over the years, creating the right environment for high-growth companies to evolve organically. In my mind UMIC, represents the best of collaboration between universities and business. " David concludes: "Our specialist markets, construction, sustainability and housing, are all experiencing tremendous growth – and as a result our specialist services and knowledge have never been more in demand." UMIC is delighted to report that Epistem has now taken the CTF 1st floor Pavilion 1. The continued success includes their recent Indian approval of import licence for the Genedrive ® TB Molecular diagnostic test and the recent announcement between Epistem and CRT for the use of patient derived Leukemic samples. UMIC are delighted to be working with Epistem at this exciting time in the company's development. 18